Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Truist Securities Downgrades Aptinyx to Hold

Truist Securities Downgrades Aptinyx to Hold

Truist Securities analyst Joon Lee downgrades Aptinyx (NASDAQ:APTX) from Buy to Hold.

byBenzinga Newsdesk

August 16, 2022

1 minute read

Truist Securities analyst Joon Lee downgrades Aptinyx (NASDAQ:APTX) from Buy to Hold.

Analyst Ratings

Where Williams-Sonoma Stands With Analysts

By Benzinga Insights

August 2, 10:00 AM

Williams-Sonoma (NYSE:WSM) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

WSM

Taiwan Semiconductor Is Top Pick For 2023, Revenue Likely To Grow 30% In FY24, Analyst Says

By Anusuya Lahiri

January 9, 1:46 PM

Needham analyst Charles Shi reiterated Buy on Taiwan Semiconductor Manufacturing Company Ltd (NYSE: TSM) with a $110 price target. Shi maintained TSMC on Needham's Conviction List and named it Top Pick for 2023.

TSM

Here’s How Much $100 Invested In Pioneer Natural Resources 20 Years Ago Would Be Worth Today

By Benzinga Insights

October 20, 4:30 PM

Pioneer Natural Resources (NYSE:PXD) has outperformed the market over the past 20 years by 4.86% on an annualized…

PXD

BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1025

By Benzinga Newsdesk

March 14, 7:34 AM

BMO Capital analyst Evan Kurtz maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $1001 to $1025.

REGN

Truist Securities Downgrades Aptinyx to Hold

Related Posts

Where Williams-Sonoma Stands With Analysts

Taiwan Semiconductor Is Top Pick For 2023, Revenue Likely To Grow 30% In FY24, Analyst Says

Here’s How Much $100 Invested In Pioneer Natural Resources 20 Years Ago Would Be Worth Today

BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1025